SCHEMBL5021041

SCHEMBL5021041

CP(C)(=O)C(F)(F)c1cc2nc(C=O)ccc2cc1Br

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 15/20 0.57
PTPRC P08575 2/20 0.49
PTPN2 P17706 5/20 0.37
CCR1 P32246 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4412462 0.88 PTPN1 (0.72) PTPN1PTPRCPTPN2
SCHEMBL5021008 0.85 PTPN1 (0.56) PTPN1PTPRCPTPN2
SCHEMBL2690743 0.84 PTPN1 (0.50) PTPN1PTPRCPTPN2
SCHEMBL5021030 0.77 PTPN1 (0.54) PTPN1PTPRCPTPN2
SCHEMBL5021027 0.76 PTPN1 (0.71) PTPN1PTPRCPTPN2
SCHEMBL4410112 0.74 PTPN1 (0.68) PTPN1PTPRCPTPN2
SCHEMBL4410114 0.74 PTPN1 (0.68) PTPN1PTPRCPTPN2
SCHEMBL15085571 0.74 PTPN1 (0.68) PTPN1PTPRCPTPN2
SCHEMBL15525075 0.73 PTPN1 (1.00) PTPN1PTPRCPTPN2
SCHEMBL15525074 0.73 PTPN1 (1.00) PTPN1PTPRCPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334295-B2 Fused aromatic PTP-1B inhibitors KANEQ PHARMA INC. (CA) 2016-05-10 US disclosed
US-20150045325-A1 FUSED AROMATIC PTP-1B INHIBITORS KANEQ PHARMA INC. (CA) 2015-02-12 US disclosed
US-8927526-B2 Fused aromatic PTP-1B inhibitors KANEQ PHARMA INC. (CA) 2015-01-06 US disclosed
US-20130281365-A1 FUSED AROMATIC PTP-1B INHIBITORS MERCK FROSST CANADA LTD. (CA) 2013-10-24 US disclosed
US-8481742-B2 Fused aromatic PTP-1B inhibitors KANEQ PHARMA INC. (CA) 2013-07-09 US disclosed
US-20120178679-A1 FUSED AROMATIC PTP-IB INHIBITORS KANEQ PHARMA INC. (CA) 2012-07-12 US disclosed
US-8168815-B2 Fused aromatic PTP-1B inhibitors KANEQ PHARMA INC. (CA) 2012-05-01 US disclosed
US-20100022477-A1 FUSED AROMATIC PTP-1B INHIBITORS KANEQ PHARMA INC. (CA) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178679-A1 FUSED AROMATIC PTP-IB INHIBITORS PTPRF, PTPRJ, PTPRCAP PTPN1 15/4885PTPRC 7/4885PTPN2 23/4885
US-20150045325-A1 FUSED AROMATIC PTP-1B INHIBITORS PTPRJ, PTPRF, PTPRCAP PTPN1 14/4885PTPRC 8/4885PTPN2 22/4885
US-20130281365-A1 FUSED AROMATIC PTP-1B INHIBITORS PTPRJ, PTPRF, PTPRCAP PTPN1 14/4885PTPRC 8/4885PTPN2 22/4885
US-20100022477-A1 FUSED AROMATIC PTP-1B INHIBITORS PTPRJ, PTPRF, PTPRCAP PTPN1 14/4885PTPRC 8/4885PTPN2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.